reallypeople? It is not complicated. The total
Post# of 148232
(Total Views: 715)
Posted On: 07/22/2020 5:06:55 PM
Re: reallypeople? #44597
reallypeople?
It is not complicated. The total scores over 4 conditions for all the patients (both arms) are averaged at baseline (day 0) and then at day 3-7-14.
Statistical analysis is run; the averages and the standard deviations (variances) of the groups calculated. p-values quantified, conclusions drawn.
The timeline will render a "tale" of recovery but what matters are the averages at day 0 and 14 (day 0 should be very similar if the groups were properly randomized).
Now, If a mild goes from say 3 to 1 in the Leronlimab group, but a moderate goes from 7 to 3 in the placebo group, what can we conclude?
This will not be good for Leronlimab group because this patient lowered the average of the placebo more than the one in Leronlimab group.
The score system is such that a jump from mild to moderate is the same that from moderate to severe and vise versa.
These are the rules we agreed with the FDA.
It is not complicated. The total scores over 4 conditions for all the patients (both arms) are averaged at baseline (day 0) and then at day 3-7-14.
Statistical analysis is run; the averages and the standard deviations (variances) of the groups calculated. p-values quantified, conclusions drawn.
The timeline will render a "tale" of recovery but what matters are the averages at day 0 and 14 (day 0 should be very similar if the groups were properly randomized).
Now, If a mild goes from say 3 to 1 in the Leronlimab group, but a moderate goes from 7 to 3 in the placebo group, what can we conclude?
This will not be good for Leronlimab group because this patient lowered the average of the placebo more than the one in Leronlimab group.
The score system is such that a jump from mild to moderate is the same that from moderate to severe and vise versa.
These are the rules we agreed with the FDA.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼